1. Questionable billing for compounded topical drugs in Medicare Part D Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018 Subject(s): Dermatologic Agents -- economicsDermatologic Agents -- therapeutic useDrug Compounding -- economicsDrug Utilization -- trendsFraudInsurance, Health, ReimbursementMedicare Part D -- economicsSkin Cream -- economicsAdministration, TopicalDermatologic Agents -- adverse effectsDrug Compounding -- standardsForecastingHealth Expenditures -- trendsInsurance CoverageSkin Cream -- adverse effectsHumansUnited StatesUnited States. Department of Health and Human Services.Centers for Medicare & Medicaid Services (U.S.)
